中红普林医疗用品股份有限公司 关于公司子公司开立募集资金专项账户 证券代码：300981 证券简称：中红医疗 公告编号：2026- 011 并签订监管协议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意中红普林医疗用品股份有限公司首 次公开发行股票注册的批复》（证监许可[2021]758 号）同意注册，中红普林 医疗用品股份有限公司（以下简称"公司"）首次公开发行人民币普通股（A 股）股票 41,670,000 股，每股面值 1.00 元，发行价为每股人民币 48.59 元， 募集资金总额为人民币 2,024,745,300.00 元，扣除发行费用总额（不含增值税） 人民币 128,288,946.26 元，实际募集资金净额为人民币 1,896,456,353.74 元， 扣除募投项目需要使用募集资金后超募资金为 1,316,713,653.74 元。募集资金 已于 2021 年 4 月 21 日到账至公司指定账户，容诚会计师事务所（特殊普通合 伙）对公司首次公开发行股票的资金到位情况进行了审验， ...

Core Viewpoint - Zhonghong Medical (300981) is expected to report significant losses for the fiscal year 2025, primarily due to industry cycles, currency fluctuations, and asset impairments [1][3]. Trading Information Summary - On January 29, Zhonghong Medical closed at 12.95 yuan, down 1.89%, with a turnover rate of 0.99%, a trading volume of 38,800 shares, and a transaction value of 50.41 million yuan [1]. - On the same day, the main funds experienced a net outflow of 5.04 million yuan, while retail investors saw a net inflow of 4.97 million yuan [1][3]. Performance Disclosure Highlights - Zhonghong Medical forecasts its total revenue for 2025 to be between 2.097 billion yuan and 2.726 billion yuan [1]. - The company anticipates a net profit loss attributable to shareholders ranging from 87 million yuan to 130 million yuan, with a non-recurring net profit loss expected to be between 125 million yuan and 186 million yuan [1][3]. Company Announcement Summary - The 2025 annual performance forecast indicates a net profit loss of 130.5 million yuan to 87 million yuan, significantly impacted by the protective glove industry's cyclical nature, exchange rate changes, and various asset impairments totaling approximately 27 million yuan to 41 million yuan for fixed assets and inventory, and 58 million yuan to 88 million yuan for goodwill [1][3].

Core Viewpoint - Zhonghong Medical is expected to report a net profit loss of 125 million to 186 million yuan for the entire year of 2025, primarily due to industry cycles, price fluctuations, and currency exchange rate impacts [1] Group 1: Performance Forecast - The company attributes the expected performance decline to several factors, including the cyclical nature and price volatility of the protective glove industry, as well as the appreciation of the RMB against the USD [1] - The company plans to recognize impairment provisions for fixed assets and inventory totaling approximately 27 million to 41 million yuan due to signs of impairment [1] - An initial assessment of goodwill related to the acquisition of Guilin Hengbao Health Protection Co., Ltd. indicates potential impairment, with expected provisions of about 58 million to 88 million yuan [1] - Non-recurring gains and losses are expected to impact the net profit attributable to shareholders by approximately 38 million to 75 million yuan, mainly from investment income and government subsidies [1] Group 2: Q3 Financial Results - For the first three quarters of 2025, the company's main revenue reached 1.864 billion yuan, a year-on-year increase of 1.38% [2] - The net profit attributable to shareholders was -7.21 million yuan, a year-on-year decrease of 114.13% [2] - The non-recurring net profit was -37.34 million yuan, a significant year-on-year decline of 20,229.69% [2] - In Q3 2025, the company's single-quarter main revenue was 626 million yuan, a year-on-year decrease of 9.24% [2] - The single-quarter net profit attributable to shareholders was -12.95 million yuan, a year-on-year decrease of 170.01% [2] - The single-quarter non-recurring net profit was -24.17 million yuan, a year-on-year decline of 691.19% [2] - The company's debt ratio stood at 28.02%, with investment income of 8.76 million yuan and financial expenses of -17.67 million yuan, while the gross profit margin was 10.54% [2]

Core Viewpoint - Zhonghong Medical is expected to report a net profit loss of between 87 million to 130 million yuan for the full year of 2025 due to various factors impacting its performance [1] Group 1: Performance Forecast - The company attributes the expected performance decline to industry cycle and price fluctuations in the protective glove sector, as well as the appreciation of the RMB against the USD [1] - The company plans to recognize impairment provisions for fixed assets and inventory totaling approximately 27 million to 41 million yuan due to signs of impairment [1] - An initial assessment of goodwill related to the acquisition of Guilin Hengbao Health Protection Co., Ltd. indicates potential impairment, with expected provisions of about 58 million to 88 million yuan [1] - Non-recurring gains and losses are anticipated to impact the net profit attributable to shareholders by approximately 38 million to 75 million yuan, mainly from investment income and government subsidies [1] Group 2: Q3 Financial Results - For the first three quarters of 2025, the company's main revenue reached 1.864 billion yuan, a year-on-year increase of 1.38% [2] - The net profit attributable to shareholders was -7.21 million yuan, a year-on-year decrease of 114.13% [2] - The company's net profit after deducting non-recurring items was -37.34 million yuan, a significant year-on-year decline of 20,229.69% [2] - In Q3 2025, the company reported a single-quarter main revenue of 626 million yuan, a year-on-year decrease of 9.24% [2] - The single-quarter net profit attributable to shareholders was -12.95 million yuan, a year-on-year decrease of 170.01% [2] - The single-quarter net profit after deducting non-recurring items was -24.17 million yuan, a year-on-year decline of 691.19% [2] - The company's debt ratio stood at 28.02%, with investment income of 8.76 million yuan and financial expenses of -17.67 million yuan, while the gross profit margin was 10.54% [2]

Core Viewpoint - Zhonghong Medical (300981.SZ) expects a net profit attributable to shareholders of the listed company to be between -130.5 million and -87 million yuan for 2025, compared to -87.13 million yuan in the same period last year [1] Group 1: Financial Performance - The net profit after deducting non-recurring gains and losses is projected to be between -186.5 million and -124.5 million yuan [1] - The company reported a significant impact on its performance due to the cyclical nature and price fluctuations in the protective glove industry, as well as the appreciation of the RMB against the USD [1] Group 2: Asset Impairment - During the reporting period, the company recognized impairment provisions for fixed assets and inventory totaling approximately 27 million to 41 million yuan due to signs of impairment [1] - The final impairment amount will be determined based on the audit data from the accounting firm [1]

Group 1 - The company expects a net profit attributable to shareholders for the year 2025 to be between -130 million and -87 million yuan, with a net profit excluding non-recurring gains and losses projected to be between -186 million and -125 million yuan [1] - The performance of the company is significantly impacted by the cyclical nature and price fluctuations in the protective glove industry, as well as the appreciation of the RMB against the USD [1]

Financial Performance - The company expects a net profit attributable to shareholders to be in the range of -130.5 million to -87 million CNY, compared to -87.13 million CNY in the same period last year [5]. - The net profit after deducting non-recurring gains and losses is projected to be between -186.5 million and -124.5 million CNY, compared to -143.46 million CNY in the previous year [5]. - The operating revenue is anticipated to be between 2.097 billion and 2.726 billion CNY, compared to 2.45665 billion CNY in the same period last year [5]. Impairment Losses - The company plans to recognize impairment losses on fixed assets and inventory totaling approximately 27 million to 41 million CNY due to signs of impairment [9]. - The company expects to recognize goodwill impairment related to the acquisition of Guilin Hengbao Health Protection Co., Ltd. in the range of 58 million to 88 million CNY [9]. Non-Recurring Items - Non-recurring gains and losses are estimated to impact the net profit attributable to shareholders by approximately 38 million to 75 million CNY, mainly from financial investment income and government subsidies [9]. Legal and Regulatory Uncertainty - The company has not yet received a ruling on the steam price arbitration case with Tangshan Wanpu Thermal Power Co., Ltd., which introduces uncertainty regarding potential liabilities and performance impact [10]. Audit Status - The financial data provided is preliminary and has not been audited by the accounting firm, but there are no discrepancies between the company and the accounting firm regarding the earnings forecast [6].

联系电话：0315-4155760 证券代码：300981 证券简称：中红医疗 公告编号：2026-009 中红普林医疗用品股份有限公司 关于公司董事会秘书取得任职培训证明并正式履职的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司（以下简称"公司"）于 2025 年 11 月 17 日召开第四届董事会第十四次会议，审议通过了《关于聘任董事会秘书的议案》， 经公司薪酬考核与提名委员会审查通过后，同意聘任邓伟先生为公司第四届董事 会的董事会秘书，上述任期自本次董事会审议通过之日起至第四届董事会任期结 束之日止。鉴于聘任时，邓伟先生尚未取得深圳证券交易所认可的董事会秘书资 格证书，董事会指定其代行董事会秘书职责，待其取得相关资格证明后，正式履 行董事会秘书职责。具体内容详见 2025 年 11 月 17 日公司在巨潮资讯网 （www.cninfo.com.cn）披露的《关于董事会秘书辞职及聘任董事会秘书的公告》 （公告编号：2025-101）。 近日，邓伟先生已取得了深圳证券交易所颁发的上市公司董事会秘书培训证 明，根据公司第四届 ...

Investment Rating - The report maintains an "Outperform" rating for the medical and biotechnology industry [1]. Core Insights - The global demand for disposable gloves has recovered to pre-pandemic levels and is expected to grow steadily, with a projected compound annual growth rate (CAGR) of approximately 10% from 2022 to 2025, reaching a sales revenue of $13.6 billion by 2025 [3][11]. - The nitrile glove segment is anticipated to see significant growth, with the global medical nitrile glove market expected to reach $7.86 billion in 2024 and $16.31 billion by 2031, reflecting a CAGR of 11.2% from 2025 to 2031 [3][28]. - The industry is transitioning towards a balanced supply-demand scenario, with a gradual recovery in prices and profitability expected as high-cost capacities are phased out [4][47]. Summary by Sections Industry Overview - Disposable gloves are primarily used in medical settings, with nitrile gloves emerging as the preferred material due to their superior properties [9][12]. Market Cycle - The industry is expected to return to a phase of volume and price increases after experiencing supply-demand fluctuations, with a notable recovery in nitrile glove demand and pricing anticipated [22][46]. Investment Recommendations - The report suggests focusing on leading companies with advantages in capacity, cost control, and global expansion, such as Yingke Medical, Zhonghong Medical, and Blue Sail Medical [5][59]. Demand Side - The demand for disposable gloves is driven by increasing healthcare spending and heightened awareness of hygiene and protection across various sectors, particularly in developed markets [25][26]. Supply Side - The supply landscape is characterized by a concentration of production in Southeast Asia and China, with domestic leading manufacturers narrowing the capacity gap with Southeast Asian competitors [34][42]. Cost and Pricing Dynamics - The production costs of gloves are significantly influenced by raw material prices, particularly nitrile latex, which constitutes about 50% of production costs [50][54]. Price trends are expected to stabilize and potentially increase as demand recovers and high-cost production capacities exit the market [57][61].

Core Viewpoint - 中红医疗 plans to engage in low-risk financial investments and hedging activities in 2026 to enhance financial stability and mitigate risks associated with currency and commodity price fluctuations [1][2][3][5] Group 1: Financial Activities - 中红医疗 intends to use up to 2 billion RMB of idle funds to invest in low-risk financial products with a maximum investment period of 36 months [5] - The company plans to conduct foreign exchange derivative transactions with a maximum balance of 500 million USD to manage currency risk, using its own funds [2][3][4] - The company aims to engage in commodity futures hedging with a total transaction amount not exceeding 50 million RMB, also funded by its own resources [2][3] Group 2: Governance and Approval - The board of 中红医疗 approved several proposals on January 19, 2026, which will be submitted for shareholder approval at the first extraordinary general meeting on February 5, 2026 [1][5] - The proposals include the use of idle funds for low-risk investments, foreign exchange derivative transactions, and commodity futures hedging, with related party transactions requiring abstention from voting by related shareholders [1][2]